Tokyo, Jan. 5 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059706) titled 'Efficacy, Safety, and Biomarker Exploration of Mepolizumab Therapy for Postoperative Recurrent Eosinophilic Chronic Rhinosinusitis: A Prospective Multicenter Cohort Study' on Jan. 5.
Study Type:
Observational
Primary Sponsor:
Institute - Graduate School of Medicine, Kyoto University
Condition:
Condition - Postoperative Recurrent Eosinophilic Chronic Rhinosinusitis
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - This study prospectively investigates the clinical outcomes of mepolizumab treatment in patients with postoperative recurrent eosinophilic chronic rhinosinusitis. We aim to evaluate whether mepolizumab improves patients' quality of life. Furthermore, by analyzing the backgrounds and clinical courses of patients who respond favorably to mepolizumab, we seek to identify clinical characteristics associated with treatment efficacy.
Basic objectives2 - Bio-availability
Eligibility:
Age-lower limit - 12
years-old
Gender - Male and Female
Key inclusion criteria - Patients with postoperative recurrent eosinophilic chronic rhinosinusitis who are currently receiving or scheduled to receive treatment with mepolizumab.
Among those, patients who have received a full explanation of the study and have provided written informed consent will be included.
Key exclusion criteria - Patients who are already receiving mepolizumab treatment for bronchial asthma or eosinophilic granulomatosis with polyangiitis.
Patients who decline to participate in this study.
Target Size - 60
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2026 Year 01 Month 05 Day
Anticipated trial start date - 2026 Year 01 Month 05 Day
Last follow-up date - 2028 Year 12 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068288
Disclaimer: Curated by HT Syndication.
